Digital Measures for Clinical Trial Endpoints in Huntington's Disease
NCT: NCT07010705 · RECRUITING
Brief Summary
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.
Frequently Asked Questions
What is Digital Measures for Clinical Trial Endpoints in Huntington's Disease?
Digital Measures for Clinical Trial Endpoints in Huntington's Disease is a clinical trial registered under NCT07010705. Current status: RECRUITING.
What is the status of NCT07010705?
The current status of NCT07010705 (Digital Measures for Clinical Trial Endpoints in Huntington's Disease) is: RECRUITING.
When did Digital Measures for Clinical Trial Endpoints in Huntington's Disease start?
Digital Measures for Clinical Trial Endpoints in Huntington's Disease started on 2025-06-20.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.